Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion
WEST CHESTER, PA — Verrica Pharmaceuticals (Nasdaq: VRCA) has dosed the first U.S. patient in a second Phase 3 clinical trial evaluating YCANTH for common warts, expanding a late-stage development …
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion Read More